Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Leukemia through trial conditions or approval indications mapped to it or to one of its descendant entities.
26 drugs · 856 active trials
42 drugs · 1,287 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Phase 2 | Phase 2 | 9 | 2 | 0 | 29 | 0 | — | — | Feb 19, 2015 |
| Tagraxofusp | Phase 2 | Phase 2 | 9 | 6 | 0 | 16 | 0 | — | — | 2013-05 |
| Tafasitamab | Phase 2 | Phase 2 | 6 | 3 | 0 | 11 | 0 | — | — | 2010-09 |
| Ipilimumab | Phase 2 | Phase 2 | 5 | 0 | 0 | 17 | 0 | — | — | 2002-03 |
| Epcoritamab | Phase 2 | Phase 2 | 5 | 2 | 0 | 6 | 0 | — | — | Mar 13, 2020 |
| Pacritinib | Phase 2 | Phase 2 | 4 | 4 | 0 | 13 | 0 | — | — | 2008-08 |
| Avapritinib | Phase 2 | Phase 2 | 4 | 3 | 0 | 7 | 0 | — | — | Mar 10, 2016 |
| Talazoparib | Phase 2 | Phase 2 | 4 | 2 | 0 | 7 | 0 | — | — | Jun 30, 2011 |
| Plerixafor | Phase 2 | Phase 2 | 3 | 2 | 0 | 26 | 0 | — | — | 2004-05 |
| Gemcitabine | Phase 2 | Phase 2 | 3 | 2 | 0 | 14 | 0 | — | — | 1999-03 |
| Ixazomib | Phase 2 | Phase 2 | 3 | 1 | 0 | 11 | 0 | — | — | 2014-03 |
| Atezolizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | Sep 15, 2015 |
| Navtemadlin | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | Apr 1, 2014 |
| Isatuximab | Phase 2 | Phase 2 | 3 | 3 | 0 | 5 | 0 | — | — | May 14, 2018 |
| Mosunetuzumab | Phase 2 | Phase 2 | 3 | 3 | 0 | 5 | 0 | — | — | Sep 15, 2015 |
| Pomalidomide | Phase 2 | Phase 2 | 3 | 2 | 0 | 5 | 0 | — | — | Dec 16, 2013 |
| Everolimus | Phase 2 | Phase 2 | 2 | 0 | 0 | 19 | 0 | — | — | 2004-04 |
| Brentuximab Vedotin | Phase 2 | Phase 2 | 2 | 2 | 0 | 11 | 0 | — | — | 2011-05 |
| Palbociclib | Phase 2 | Phase 2 | 2 | 1 | 0 | 9 | 0 | — | — | 2012-09 |
| Trametinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 7 | 0 | — | — | Aug 12, 2009 |
| Binimetinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | 2012-03 |
| Durvalumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | May 11, 2016 |
| Mogamulizumab | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | Feb 26, 2020 |
| Tyrosine Kinase Inhibitor | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Aug 8, 2012 |
| Vemurafenib | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | 2012-10 |
| Lisocabtagene Maraleucel | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Nov 27, 2017 |
| Polatuzumab Vedotin | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Mar 22, 2011 |
| Ropeginterferon Alfa-2b | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Aug 30, 2013 |
| Aspirin | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Oct 3, 2019 |
| Brexucabtagene Autoleucel | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Dec 18, 2018 |
| Capivasertib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Mar 17, 2026 |
| Momelotinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | May 22, 2024 |
| Bevacizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 15 | 0 | — | — | 2001-04 |
| Valproic Acid | Phase 2 | Phase 2 | 1 | 1 | 0 | 11 | 0 | — | — | Jan 23, 2004 |
| Carfilzomib | Phase 2 | Phase 2 | 1 | 1 | 0 | 10 | 0 | — | — | 2010-08 |
| Metformin | Phase 2 | Phase 2 | 1 | 1 | 0 | 9 | 0 | — | — | Jul 18, 2011 |
| Avelumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | 2016-07 |
| Oxaliplatin | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2004-11 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Jul 10, 2019 |
| Veliparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2006-06 |
| Cobimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Mar 9, 2016 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2008-07 |
| Cisplatin | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 1997-06 |
| Leuprolide | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 19, 2011 |
| Olaparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 1, 2020 |
| Pegargiminase | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jan 6, 2015 |
| Selumetinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2007-12 |
| Zoledronic Acid | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-07 |
| Camrelizumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 25, 2020 |
| Epirubicin | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2003-03 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.